aspirin has been researched along with Body Weight in 219 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 9.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| "To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation." | 9.08 | Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995) |
| "Soluble aspirin was given by mouth in therapeutic doses in a double-blind trial to malnourished infants and young children with gastroenteritis and dehydration." | 9.05 | Reduction by aspirin of intestinal fluid-loss in acute childhood gastroenteritis. ( Burke, V; Gracey, M, 1980) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 8.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| " Aspirin is known as a potent anti-inflammatory drug, but its role in adipogenesis, adipocyte-specific inflammation, and metabolic syndrome is not well characterized." | 8.12 | Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice. ( Ahmed, F; Amin, MT; Begum, R; Bhowmik, DR; Hossain, MS; Islam, MA; Roy, S, 2022) |
| "The protective effect of aspirin against myocardial hypertrophy (MH) was studied." | 8.02 | The Protective Effect of Aspirin against Myocardial Hypertrophy in Rats. ( Fan, X; Liu, J; Ma, X; Wei, M; Wu, X; Xue, M; Zhang, H, 2021) |
| "The patients with high body weight, the CYP2C19 phenotypes, and P2Y12 receptor (52 G >T) variant alleles are at risk of CR during clopidogrel treatment in Chinese IS patients with aspirin intolerance." | 7.96 | Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance. ( Dong, W; He, X; Hu, H; Kong, Y; Li, Y; Li, Z; Sun, L; Wang, C; Wang, Y; Yang, D; Zhang, J; Zhao, M, 2020) |
| "To study whether effect of aspirin plus low-dose diethylstilbestrol is more effective and safer than high diethylstilbestrol dose alone on prevention of ovariectomy-induced osteopenia and dyslipidemia." | 7.79 | Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. ( Cui, L; Huang, JP; Lin, SE; Wu, LZ; Wu, T, 2013) |
| "Aspirin is associated with a reduced risk of colorectal cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway which is thought to play an important role in intestinal inflammation and the tumorigenesis of CRC." | 7.77 | Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. ( Chen, H; Gao, W; Mao, X; Ren, C; Song, T; Tian, Y; Wang, D; Ye, Y, 2011) |
| " The aim of the present study was to examine the effect of chronic administration of aspirin on metabolic and cardiovascular parameters in fructose-fed rats (FFR), an experimental model of metabolic syndrome." | 7.75 | Effect of chronic aspirin administration on an experimental model of metabolic syndrome. ( González, ES; Lama, MC; Miatello, RM; Renna, NF; Vazquez, MA, 2009) |
| "To investigate the effect of a combination of carnosine and aspirin eye drops on the progression of diabetic cataract formation induced by streptozotocin (STZ)." | 7.75 | Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats. ( Harding, JJ; Li, MY; Shi, Q; Yan, H, 2009) |
| " The aims of the present study were: to verify the incidence of Normal Weight Obese (NWO) syndrome; to evaluate by PINI the effect of 8 weeks acetyl salicylic (100 mg/die) and atorvastatin (10 mg/die) combined treatment on chronic inflammation in 52 selected HD patients." | 7.74 | Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. ( De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C, 2008) |
| "To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of glycation, on the development of diabetic cataract in rat." | 7.74 | Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. ( Ding, Z; Guo, Y; Ha, W; Harding, JJ; Yan, H; Zhang, J, 2008) |
| "Aspirin prevented and partially reversed ACTH-induced hypertension in the SD rats." | 7.74 | Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat. ( Miao, Y; Whitworth, JA; Zhang, Y, 2007) |
| "Chronic in vivo treatment with aspirin prevented the development of hypertension and reduced insulin resistance significantly in chronically glucose-fed rats." | 7.71 | Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. ( de Champlain, J; El Midaoui, A; Wu, R, 2002) |
| "We have studied the effect of lysine acetylsalicylate (LAS; Aspegic), a soluble salt of aspirin, on motor deficits in transgenic mice expressing a human superoxide dismutase SOD1 mutation (Gly-93 --> Ala), an animal model of familial amyotrophic lateral sclerosis (FALS)." | 7.70 | Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. ( Barnéoud, P; Curet, O, 1999) |
| "Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats." | 7.70 | Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis. ( Jayakumar, R; Jayasundar, S; Malarvannan, P; Puvanakrishnan, R; Ramesh, CV, 1998) |
| "Prophylactic effects of sulfinpyrazone (100 mg/Kg), aspirin (5 mg/Kg, 50 mg/Kg), and propranolol (2 mg/Kg, 10 mg/Kg) on myocardial necrosis and hypertrophy induced by isoproterenol were examined." | 7.66 | Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis. ( Hashimoto, H; Ogawa, K, 1981) |
| "The effect of different dosage regimens of aspirin was investigated in an experimental model of arterial thrombosis." | 7.66 | Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis. ( Mörl, H; Thiessen, M; Walter, E; Zimmermann, R, 1980) |
| "Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice." | 5.51 | Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019) |
| " During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight." | 5.27 | Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. ( Abernethy, DR; Boxenbaum, HG; Greenblatt, DJ; Harmatz, JS; Matlis, R; Ochs, HR; Shader, RI, 1986) |
| "Obesity is associated with substantially increased CRC risk in patients with LS, but this risk is abrogated in those taking aspirin." | 5.20 | Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. ( Bertario, L; Bisgaard, ML; Bishop, DT; Burn, J; Dunlop, MG; Eccles, D; Evans, DG; Ho, JW; Hodgson, SV; Lindblom, A; Lubinski, J; Macrae, F; Maher, ER; Mathers, JC; Mecklin, JP; Moeslein, G; Morrison, PJ; Movahedi, M; Murday, V; Olschwang, S; Ramesar, RS; Scott, RJ; Side, L; Thomas, HJ; Vasen, HF, 2015) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| "We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension." | 5.16 | Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. ( Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012) |
| "To determine any benefits or risks, expressed in early childhood, of low dose aspirin treatment in pregnancies at high risk of complications due to pre-eclampsia or intrauterine growth retardation." | 5.08 | Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. ( , 1995) |
| "Soluble aspirin was given by mouth in therapeutic doses in a double-blind trial to malnourished infants and young children with gastroenteritis and dehydration." | 5.05 | Reduction by aspirin of intestinal fluid-loss in acute childhood gastroenteritis. ( Burke, V; Gracey, M, 1980) |
| " Lush reviews positive and negative aspects of recent trends and summarizes the results of studies on the prophylactic potential of maintenance of normal body weight, exercise, aspirin, fish oils, estrogens, and antioxidants." | 4.78 | Coronary artery disease. The latest on prevention. ( Lush, DT, 1992) |
| "Bleeding is the most common adverse reaction to aspirin and can lead to drug discontinuation or even be life-threatening in the secondary prevention of stroke or transient ischemic attack." | 4.12 | Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients. ( Cheng, J; Deng, X; Li, H; Ma, Y; Shi, T; Wang, X; Wu, Y; Zhang, Z; Zhu, Q, 2022) |
| " Aspirin is known as a potent anti-inflammatory drug, but its role in adipogenesis, adipocyte-specific inflammation, and metabolic syndrome is not well characterized." | 4.12 | Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice. ( Ahmed, F; Amin, MT; Begum, R; Bhowmik, DR; Hossain, MS; Islam, MA; Roy, S, 2022) |
| "The protective effect of aspirin against myocardial hypertrophy (MH) was studied." | 4.02 | The Protective Effect of Aspirin against Myocardial Hypertrophy in Rats. ( Fan, X; Liu, J; Ma, X; Wei, M; Wu, X; Xue, M; Zhang, H, 2021) |
| "The patients with high body weight, the CYP2C19 phenotypes, and P2Y12 receptor (52 G >T) variant alleles are at risk of CR during clopidogrel treatment in Chinese IS patients with aspirin intolerance." | 3.96 | Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance. ( Dong, W; He, X; Hu, H; Kong, Y; Li, Y; Li, Z; Sun, L; Wang, C; Wang, Y; Yang, D; Zhang, J; Zhao, M, 2020) |
| "Suboptimal platelet response to aspirin was detected in 64 of 430 patients (15%) and thrombosis was detected in 11 patients (2." | 3.85 | Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery. ( DiNardo, JA; Emani, S; Emani, SM; Mulone, M; Trenor, CC; Zurakowski, D, 2017) |
| " Two subgroups of GK and Wistar control rats were injected intraperitoneally with 100 mg aspirin/kg body weight/ day for 5 weeks." | 3.81 | Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats. ( Adeghate, E; Amiri, L; Howarth, FC; Jayaprakash, P; John, A; Raza, H; Shafarin, J; Yasin, J, 2015) |
| "Overall, this study suggested that both celecoxib and aspirin could prevent breast cancer growth by regulating proteins in the cell cycle and apoptosis without blocking estrogen synthesis." | 3.80 | Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice. ( Chan, FL; Chen, S; Leung, LK; Li, F; Lin, SM; Wong, TY, 2014) |
| "To study whether effect of aspirin plus low-dose diethylstilbestrol is more effective and safer than high diethylstilbestrol dose alone on prevention of ovariectomy-induced osteopenia and dyslipidemia." | 3.79 | Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol. ( Cui, L; Huang, JP; Lin, SE; Wu, LZ; Wu, T, 2013) |
| "Aspirin is associated with a reduced risk of colorectal cancer (CRC), and it showed inhibited effects on interleukin 6 (IL-6)/signal transducer and activator of transcription 3 (STAT3) signaling pathway which is thought to play an important role in intestinal inflammation and the tumorigenesis of CRC." | 3.77 | Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. ( Chen, H; Gao, W; Mao, X; Ren, C; Song, T; Tian, Y; Wang, D; Ye, Y, 2011) |
| "Data obtained in this study suggest a suboptimal clopidogrel response in patients with greater body weight and body mass index." | 3.77 | Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. ( Alexander, MJ; Choulakian, A; Drazin, D; Kornbluth, P; Nuño, M, 2011) |
| " The aim of the present study was to examine the effect of chronic administration of aspirin on metabolic and cardiovascular parameters in fructose-fed rats (FFR), an experimental model of metabolic syndrome." | 3.75 | Effect of chronic aspirin administration on an experimental model of metabolic syndrome. ( González, ES; Lama, MC; Miatello, RM; Renna, NF; Vazquez, MA, 2009) |
| "To investigate the effect of a combination of carnosine and aspirin eye drops on the progression of diabetic cataract formation induced by streptozotocin (STZ)." | 3.75 | Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats. ( Harding, JJ; Li, MY; Shi, Q; Yan, H, 2009) |
| "Aspirin prevented and partially reversed ACTH-induced hypertension in the SD rats." | 3.74 | Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat. ( Miao, Y; Whitworth, JA; Zhang, Y, 2007) |
| "To investigate the effect of carnosine (CA), aminoguanidine (AG), and aspirin (ASA) drops, all inhibitors of glycation, on the development of diabetic cataract in rat." | 3.74 | Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats. ( Ding, Z; Guo, Y; Ha, W; Harding, JJ; Yan, H; Zhang, J, 2008) |
| " The aims of the present study were: to verify the incidence of Normal Weight Obese (NWO) syndrome; to evaluate by PINI the effect of 8 weeks acetyl salicylic (100 mg/die) and atorvastatin (10 mg/die) combined treatment on chronic inflammation in 52 selected HD patients." | 3.74 | Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. ( De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C, 2008) |
| " Diabetes was induced in Wistar male rats by single injection of streptozotocin, resulting after 8 weeks in significant body weight reduction, increased plasma glucose concentrations, and decreased plasma C-peptide levels, compared to non-diabetic animals." | 3.74 | French maritime pine bark extract Pycnogenol reduces thromboxane generation in blood from diabetic male rats. ( Durackova, Z; Muchova, J; Nocun, M; Ulicna, O; Watala, C, 2008) |
| "Chronic in vivo treatment with aspirin prevented the development of hypertension and reduced insulin resistance significantly in chronically glucose-fed rats." | 3.71 | Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats. ( de Champlain, J; El Midaoui, A; Wu, R, 2002) |
| "The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin." | 3.71 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002) |
| "Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats." | 3.70 | Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis. ( Jayakumar, R; Jayasundar, S; Malarvannan, P; Puvanakrishnan, R; Ramesh, CV, 1998) |
| "We have studied the effect of lysine acetylsalicylate (LAS; Aspegic), a soluble salt of aspirin, on motor deficits in transgenic mice expressing a human superoxide dismutase SOD1 mutation (Gly-93 --> Ala), an animal model of familial amyotrophic lateral sclerosis (FALS)." | 3.70 | Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis. ( Barnéoud, P; Curet, O, 1999) |
| "The effect of different dosage regimens of aspirin was investigated in an experimental model of arterial thrombosis." | 3.66 | Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis. ( Mörl, H; Thiessen, M; Walter, E; Zimmermann, R, 1980) |
| "Prophylactic effects of sulfinpyrazone (100 mg/Kg), aspirin (5 mg/Kg, 50 mg/Kg), and propranolol (2 mg/Kg, 10 mg/Kg) on myocardial necrosis and hypertrophy induced by isoproterenol were examined." | 3.66 | Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis. ( Hashimoto, H; Ogawa, K, 1981) |
| "Aspirin and selenium have been shown in vitro and in vivo to inhibit HIV production through inhibition of the transcription factor, the nuclear factor kappa binding (NF-eB)." | 2.73 | Selenium and aspirin in people living with HIV and AIDS in Nigeria. ( Adediran, IA; Akinola, NO; Armistead, H; Durosinmi, MA; Elujoba, AA; Falola, OL; Irinoye, O; Muraina, HA; Odusoga, OL; Ogun, SA; Olasode, OA; Onayemi, O, 2008) |
| "Five aspirin preparations were evaluated, 3 different enteric-coated 75-mg aspirins, dispersible aspirin 75 mg and asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily)." | 2.72 | Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. ( Byrne, MF; Conroy, R; Cox, D; Dooley, M; Fitzgerald, DJ; Maree, AO, 2006) |
| "Although pharmacologic treatment for hyperlipidemia had the greatest favorable impact on the ratio over time, our data also show that maintaining an ideal weight and exercise have beneficial effects." | 2.71 | Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men. ( Buring, JE; Gaziano, JM; Levenson, JW; Scranton, R; Sesso, HD; Stampfer, MJ, 2004) |
| "The relationship between anthropometric data and pharmacokinetic characteristics of acetylsalicylic acid (ASA) after administration of a single oral dose of 500 mg ASA, an oral and intravenous dose of 500 mg D,L-lysine-mono-acetylsalicylate (Lys-ASA) and an oral dose of 1,000 mg Lys-ASA were evaluated." | 2.70 | Anthropometric data and acetylsalicylic acid pharmacokinetics. ( Koch, HJ; Raschka, C, 2002) |
| " The symptoms of salicylism correlated closely with serum salicylate levels, which, in turn, correlated well with the dosage in g/m2." | 2.65 | Dosage of salicylates for children with juvenile rheumatoid arthritis. A prospective clinical trial with three different preparations of acetylsalicylic acid. ( Mäkela, AL; Mattila, M; Yrjänä, T, 1979) |
| "Aspirin tended to increase jejunal CLDN-1 mRNA expression (P = 0." | 1.56 | Use of aspirin to intentionally induce gastrointestinal tract barrier dysfunction in feedlot cattle. ( Brennan, KM; Briggs, NG; Funnell, BJ; Nicholls, GT; Schoonmaker, JP, 2020) |
| "Aspirin treatment reduced body weight gain, reversed glucose intolerance, and depressed hepatic lipid accumulation in female, but not in male mice." | 1.51 | Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero. ( Drake, M; Hao, Y; Jendrusch, C; Liu, Z; Peng, H; Xie, L; Zhang, KK; Zhou, Y, 2019) |
| "A one-dose-fits-all approach to use of aspirin has yielded only modest benefits in long-term prevention of cardiovascular events, possibly due to underdosing in patients of large body size and excess dosing in patients of small body size, which might also affect other outcomes." | 1.48 | Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. ( Belch, JFF; Cook, NR; Gaziano, JM; Mehta, Z; Morimoto, T; Price, JF; Roncaglioni, MC; Rothwell, PM, 2018) |
| " Long-term administration of enteric-coated aspirin and ibuprofen induced the metabolic activity of the CYP450 enzyme." | 1.48 | Metabolism of liver CYP450 and ultrastructural changes after long-term administration of aspirin and ibuprofen. ( Chen, Z; Hu, L; Lin, Y; Song, H; Tong, S; Wang, X; Wen, C; Zhan, H; Zhuang, Z, 2018) |
| " Rats in AEE-treated group were fed with HFD for 8 weeks to induce hyperlipidemia, and then given AEE once daily by oral gavage for 5 weeks at the dosage of 54 mg/kg body weight." | 1.46 | Feces and liver tissue metabonomics studies on the regulatory effect of aspirin eugenol eater in hyperlipidemic rats. ( Dong, P; Jiao, Z; Kong, X; Li, J; Li, S; Liu, X; Ma, N; Qin, Z; Yang, Y, 2017) |
| "Aspirin treatment significantly prevented bone loss by increasing bone formation." | 1.43 | Aspirin prevents bone loss with little mechanical improvement in high-fat-fed ovariectomized rats. ( Cui, L; Fu, Z; Huang, J; Huang, M; Lee, WYW; Li, G; Liang, Y; Lin, S; Suen, CW; Wu, H; Wu, T; Xu, L, 2016) |
| " Hence, objective of the current study was to investigate the potential toxic effects of ACS c-SLN combined chemopreventive regimens following acute (3 days), subacute (28 days), and subchronic (90 days) administrations by oral gavage in BALB/c mice." | 1.43 | Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. ( Chenreddy, S; Khamas, W; Prabhu, S; Thakkar, A; Thio, A; Wang, J, 2016) |
| "Aspirin treatment also reduced right ventricular hypertrophy and pulmonary arteriole proliferation in ASA-treated PAH model." | 1.37 | Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. ( He, B; Pu, J; Shen, J; Shen, L, 2011) |
| " In this study, we investigated the effect of high-dose and long-term use of acetyl salicylic acid (ASA) on the streptozotocin-induced diabetic rats as a model of type I diabetes, with consideration on the structure and/or function of proteins." | 1.35 | Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats. ( Bathaie, SZ; Hassan, MZ; Jafarnejad, A; Nakhjavani, M, 2008) |
| " Unlike general toxicity data, their prenatal toxic effects were not extensively studied before." | 1.33 | Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study. ( Burdan, F, 2005) |
| "PHA-798 reduced thrombus formation on the thrombogenic surface in a dose-dependent manner (56+/-1." | 1.32 | Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. ( Blom, JD; Case, BL; LaChance, RM; Nicholson, NS; Panzer-Knodle, SG; Parlow, JJ; Salyers, AK; South, MS; Suleymanov, OD; Szalony, JA; Wood, RS, 2003) |
| " The objectives of the current study were to comprehensively define the developmental toxicology profile of ASA in rabbits by using a dosing paradigm encompassing the period of organogenesis and to test the hypothesis that maternal gastrointestinal toxicity after repeated dose administrations hampers the detection of low-incidence malformations with ASA in rabbits by limiting ASA administration to sensitive windows for cardiovascular development and midline closure." | 1.32 | Comparison of the developmental toxicity of aspirin in rabbits when administered throughout organogenesis or during sensitive windows of development. ( Cappon, GD; Cook, JC; Gupta, U; Hurtt, ME; Tassinari, MS, 2003) |
| " There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17." | 1.32 | Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms. ( Cook, JC; Gupta, U; Hurtt, ME; Tassinari, MS, 2003) |
| "Hypertension was induced in adult male Wistar rats using Methylprednisolone (MP) 20 mg/kg per week s." | 1.32 | Potential adverse interaction between aspirin and lisinopril in hypertensive rats. ( Balani, DK; Dubey, K; Pillai, KK, 2003) |
| "Both COX inhibitors were toxic to dams in the highest doses evaluated, which caused a significantly greater incidence of intrauterine growth retardation and developmental variations." | 1.32 | Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats. ( Burdan, F, 2004) |
| "Aspirin was associated with increased blood concentrations of 3MEIN-adduct for diets that did not contain supplemental vitamin E." | 1.31 | Effects of feeding aspirin and supplemental vitamin E on plasma concentrations of 3-methylindole, 3-methyleneindolenine-adduct concentrations in blood and pulmonary tissues, lung lesions, and growth performance in feedlot cattle. ( Bray, TM; Loneragan, GH; Mason, GL; Morley, PS; Thoren, MA; Wagner, JJ; Wittum, TE; Yost, GS, 2002) |
| "Aspirin (400 ppm) has a similar impact on reducing prostaglandin levels, but in contrast to indomethacin, is uneffective in reducing the tumor load." | 1.31 | Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice. ( Chiu, CH; McEntee, MF; Whelan, J, 2000) |
| "Aspirin treatment significantly increased activity during the first and second dark cycles after surgery, whereas buprenorphine significantly increased activity during the second dark cycle only." | 1.31 | Oral buprenorphine and aspirin analgesia in rats undergoing liver transplantation. ( Howden, BO; Jablonski, P, 2002) |
| " The study illustrates the need for pharmacokinetic data to establish the individual doses of drugs, particularly in conditions that alter nutritional status." | 1.30 | Influence of nutritional status on the pharmacokinetics of acetylsalicylic acid and its metabolites in children with autoimmune disease. ( Carbajal-Rodríguez, L; Flores-Pérez, J; Juárez-Olguín, H; Lares-Asseff, I; Loredo-Abdalá, A; Ramírez-Lacayo, M, 1999) |
| " exposures of microwave radiation [Specific Absorption Rate = 0." | 1.30 | Acetaminophen effects on behavioral thermoregulation in albino rats. ( Blake, SE; Kaiser, GA; Luper, SL; Maranto, DL; McPherson, KP; Storey, TM; Vitulli, WF, 1999) |
| "Aspirin-treated P cows had longer PP intervals than either control P, control M, or aspirin-treated M cows." | 1.30 | The effect of aspirin administration and parity on plasma salicylate concentrations and postpartum reproductive parameters in Brahman cows. ( Neuendorff, DA; Randel, RD; Stahringer, RC, 1999) |
| "Aspirin was given once daily via the oral-gastric route, and blood samples were obtained after the third dose." | 1.29 | Disposition kinetics of aspirin in female New Zealand white rabbits. ( Marangos, MN; Nicolau, DP; Nightingale, CH; Onyeji, CO, 1995) |
| "Patients admitted to the coronary care unit who received both intravenous nitroglycerin and heparin were studied to evaluate heparin dosage requirements." | 1.29 | Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease. ( Berk, SI; Bodenheimer, MM; Grunwald, A; Pal, S, 1993) |
| "Aspirin treatment significantly lowered plasma prostaglandin F2 alpha concentration, but did not affect liver lipid concentrations." | 1.29 | Involvement of (n-6) essential fatty acids and prostaglandins in liver lipid accumulation in Japanese quail. ( Furuse, M; Murai, A; Okumura, J, 1996) |
| "The analgesic drug combination Thomapyrin consisting of acetylsalicylic acid (CAS 50-78-2, ASA), paracetamol (CAS 103-90-2, NAPAP) and caffeine (CAS 58-08-2) in the ratio 5:4:1 was investigated for its chronic toxicity in rats." | 1.29 | Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys. ( Bauer, E; Bauer, M; Greischel, A; Hirsch, U; Lehmann, H; Schmid, J; Schneider, P, 1996) |
| " Combination with ASA potentiated the toxic effect of the aminoglycoside after 10 but not after 5 days of treatment." | 1.27 | Prostaglandins and aminoglycoside nephrotoxicity. ( Assael, BM; Bamonte, F; Chiabrando, C; Gagliardi, L; Noseda, A; Salmona, M, 1985) |
| "Aspirin is an inhibitor of prostaglandin H synthase and has been shown to inhibit FANFT-induced bladder carcinogenesis when coadministered in the diet." | 1.27 | Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats. ( Cohen, SM; Hasegawa, R; Johansson, SL; Sakata, T; Zenser, TV, 1986) |
| " During long-term therapy, salicylate dosage for obese individuals should not be adjusted upward in proportion to total weight." | 1.27 | Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. ( Abernethy, DR; Boxenbaum, HG; Greenblatt, DJ; Harmatz, JS; Matlis, R; Ochs, HR; Shader, RI, 1986) |
| "Aspirin was given by continuous intravenous infusion to 35 intact cats for 7 days in doses ranging from 25 to 200 mg kg-1 day-1." | 1.26 | Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. ( Aures, D; Bugat, R; Grossman, MI; Thompson, MR, 1976) |
| "A young patient with Bartter's syndrome was treated for three months with 100 mg/kg/day of aspirin to inhibit prostaglandin synthesis." | 1.26 | Prostaglandins and aspirin therapy in Bartter's syndrome. ( Flamenbaum, W; Lentz, R; Norby, L; Ramwell, P, 1976) |
| " During the dosing period, females received 300mg/kg of M73101 showed pronounced body weight depression and decrease in food and water intake." | 1.26 | [Reproduction study of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101) in rabbits. Administration of M73101 during the period of major organogenesis (author's transl)]. ( Kosazuma, T; Obori, R; Tanaka, H; Tanigawa, H; Yoshida, J, 1979) |
| "The labeled dosage schedule that has long been on pediatric aspirin preparations is at variance with the recommendation in authoritative medical references, studies demonstrating antipyretic effectiveness in children, and the prescribing habits of pediatricians as revealed by a poll conducted by the authors." | 1.26 | Aspirin dosage for infants and children. ( Clayton, JM; Done, AK; Yaffe, SJ, 1979) |
| "Aspirin treatment, 150 mg/kg twice daily, inhibited growth of a transplantable mast-cell ascites tumor (P815) by 39-43% (p less than 0." | 1.26 | Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. ( Beaven, MA; Hial, V; Horakova, Z; Shaff, FE, 1976) |
| "Male Wistar rats were dosed daily by gavage for 200 days with either (1) aspirin, 200 mg/kg; (2) acetaminophen, 200 mg/kg; (3) aspirin and acetaminophen, 200 mg/kg of each; (4) aspirin and acetaminophen, 100 mg/kg of each or (5) vehicle alone." | 1.26 | Failure to observe pathology in the rat following chronic dosing with acetaminophen and acetylsalicylic acid. ( Nera, EA; Thomas, BH; Zeitz, W, 1977) |
| "Indomethacin and aspirin treatment of animals injected with PMSG also reduced the ovarian weight gain." | 1.25 | The effect of inhibition of prostaglandin synthesis on ovarian hypertrophy in the rat. ( Castracane, VD; Shaikh, AA; Tankenow, LF, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 103 (47.03) | 18.7374 |
| 1990's | 29 (13.24) | 18.2507 |
| 2000's | 42 (19.18) | 29.6817 |
| 2010's | 35 (15.98) | 24.3611 |
| 2020's | 10 (4.57) | 2.80 |
| Authors | Studies |
|---|---|
| Khanum, SA | 1 |
| Khanum, NF | 1 |
| Shashikanth, M | 1 |
| Wang, X | 2 |
| Zhu, Q | 1 |
| Wu, Y | 1 |
| Li, H | 1 |
| Deng, X | 1 |
| Cheng, J | 1 |
| Zhang, Z | 1 |
| Ma, Y | 1 |
| Shi, T | 1 |
| Heffron, SP | 1 |
| Windheim, J | 1 |
| Barrett, TJ | 1 |
| Voora, D | 1 |
| Berger, JS | 1 |
| Roy, S | 1 |
| Bhowmik, DR | 1 |
| Begum, R | 1 |
| Amin, MT | 1 |
| Islam, MA | 1 |
| Ahmed, F | 1 |
| Hossain, MS | 1 |
| Brustugun, J | 1 |
| Notaker, N | 1 |
| Paetz, LH | 1 |
| Tho, I | 1 |
| Bjerknes, K | 1 |
| Woods, RL | 1 |
| Polekhina, G | 1 |
| Wolfe, R | 1 |
| Nelson, MR | 1 |
| Ernst, ME | 1 |
| Reid, CM | 1 |
| Shah, RC | 1 |
| Lockery, JE | 1 |
| Orchard, SG | 1 |
| Murray, AM | 1 |
| McNeil, JJ | 1 |
| Li, Z | 1 |
| Dong, W | 1 |
| Yang, D | 1 |
| Sun, L | 1 |
| He, X | 1 |
| Hu, H | 1 |
| Zhang, J | 3 |
| Wang, C | 1 |
| Li, Y | 1 |
| Zhao, M | 1 |
| Kong, Y | 1 |
| Wang, Y | 1 |
| Briggs, NG | 1 |
| Brennan, KM | 1 |
| Funnell, BJ | 1 |
| Nicholls, GT | 1 |
| Schoonmaker, JP | 1 |
| Oh, YJ | 1 |
| Kim, AJ | 1 |
| Ro, H | 1 |
| Chang, JH | 1 |
| Lee, HH | 1 |
| Chung, W | 1 |
| Hyun, YY | 1 |
| Lee, J | 1 |
| Kim, YH | 1 |
| Han, SH | 1 |
| Chae, DW | 1 |
| Ahn, C | 1 |
| Oh, KH | 1 |
| Jung, JY | 1 |
| Wang, CF | 1 |
| Cai, XR | 1 |
| Chi, YN | 1 |
| Miao, XY | 1 |
| Yang, JY | 1 |
| Xiao, BK | 1 |
| Huang, RQ | 1 |
| Wu, X | 1 |
| Wei, M | 1 |
| Zhang, H | 1 |
| Fan, X | 1 |
| Ma, X | 1 |
| Liu, J | 1 |
| Xue, M | 1 |
| Emani, S | 1 |
| Zurakowski, D | 1 |
| Mulone, M | 1 |
| DiNardo, JA | 1 |
| Trenor, CC | 1 |
| Emani, SM | 1 |
| Masuda, T | 1 |
| Yano, F | 1 |
| Omura, N | 1 |
| Tsuboi, K | 1 |
| Hoshino, M | 1 |
| Yamamoto, SR | 1 |
| Akimoto, S | 1 |
| Kashiwagi, H | 1 |
| Yanaga, K | 1 |
| Ma, N | 1 |
| Liu, X | 2 |
| Kong, X | 1 |
| Li, S | 1 |
| Jiao, Z | 1 |
| Qin, Z | 1 |
| Dong, P | 1 |
| Yang, Y | 2 |
| Li, J | 2 |
| El-Kholy, MS | 1 |
| El-Hindawy, MM | 1 |
| Alagawany, M | 1 |
| Abd El-Hack, ME | 1 |
| El-Sayed, SAA | 1 |
| Rothwell, PM | 1 |
| Cook, NR | 1 |
| Gaziano, JM | 2 |
| Price, JF | 1 |
| Belch, JFF | 1 |
| Roncaglioni, MC | 1 |
| Morimoto, T | 1 |
| Mehta, Z | 1 |
| Lim, GB | 1 |
| Wen, C | 1 |
| Zhuang, Z | 1 |
| Song, H | 1 |
| Tong, S | 1 |
| Lin, Y | 1 |
| Zhan, H | 1 |
| Chen, Z | 1 |
| Hu, L | 1 |
| Zhou, Y | 1 |
| Peng, H | 1 |
| Liu, Z | 2 |
| Zhang, KK | 1 |
| Jendrusch, C | 1 |
| Drake, M | 1 |
| Hao, Y | 1 |
| Xie, L | 1 |
| Stovitz, SD | 1 |
| Damen, SAJ | 1 |
| Brouwer, MA | 1 |
| Kramers, C | 1 |
| Lin, SE | 1 |
| Huang, JP | 1 |
| Wu, LZ | 1 |
| Wu, T | 2 |
| Cui, L | 2 |
| Morgan, DR | 1 |
| Arrow, J | 1 |
| Smith, MP | 1 |
| Altintas, R | 1 |
| Polat, A | 1 |
| Parlakpinar, H | 1 |
| Vardi, N | 1 |
| Beytur, A | 1 |
| Oguz, F | 1 |
| Sagir, M | 1 |
| Yildiz, A | 1 |
| Duran, ZR | 1 |
| Lin, HL | 1 |
| Yen, HW | 1 |
| Hsieh, SL | 1 |
| An, LM | 1 |
| Shen, KP | 1 |
| Wong, TY | 1 |
| Li, F | 1 |
| Lin, SM | 1 |
| Chan, FL | 1 |
| Chen, S | 1 |
| Leung, LK | 1 |
| Dei, HK | 1 |
| Vengoechea, F | 1 |
| Lai, Y | 1 |
| Zhong, W | 1 |
| Yu, T | 1 |
| Xia, ZS | 1 |
| Li, JY | 1 |
| Ouyang, H | 1 |
| Shan, TD | 1 |
| Yang, HS | 1 |
| Chen, QK | 1 |
| Amiri, L | 1 |
| John, A | 1 |
| Shafarin, J | 1 |
| Adeghate, E | 1 |
| Jayaprakash, P | 1 |
| Yasin, J | 1 |
| Howarth, FC | 1 |
| Raza, H | 1 |
| Movahedi, M | 1 |
| Bishop, DT | 1 |
| Macrae, F | 1 |
| Mecklin, JP | 1 |
| Moeslein, G | 1 |
| Olschwang, S | 1 |
| Eccles, D | 1 |
| Evans, DG | 1 |
| Maher, ER | 1 |
| Bertario, L | 1 |
| Bisgaard, ML | 1 |
| Dunlop, MG | 1 |
| Ho, JW | 1 |
| Hodgson, SV | 1 |
| Lindblom, A | 1 |
| Lubinski, J | 1 |
| Morrison, PJ | 1 |
| Murday, V | 1 |
| Ramesar, RS | 1 |
| Side, L | 1 |
| Scott, RJ | 1 |
| Thomas, HJ | 1 |
| Vasen, HF | 1 |
| Burn, J | 1 |
| Mathers, JC | 1 |
| Thakkar, A | 1 |
| Chenreddy, S | 1 |
| Thio, A | 1 |
| Khamas, W | 1 |
| Wang, J | 1 |
| Prabhu, S | 1 |
| Lin, S | 1 |
| Lee, WYW | 1 |
| Huang, M | 1 |
| Fu, Z | 1 |
| Liang, Y | 1 |
| Wu, H | 1 |
| Xu, L | 1 |
| Suen, CW | 1 |
| Huang, J | 1 |
| Li, G | 1 |
| Renna, NF | 1 |
| Vazquez, MA | 1 |
| Lama, MC | 1 |
| González, ES | 1 |
| Miatello, RM | 1 |
| Yan, H | 2 |
| Guo, Y | 1 |
| Ding, Z | 1 |
| Ha, W | 1 |
| Harding, JJ | 2 |
| Durosinmi, MA | 1 |
| Armistead, H | 1 |
| Akinola, NO | 1 |
| Onayemi, O | 1 |
| Adediran, IA | 1 |
| Olasode, OA | 1 |
| Elujoba, AA | 1 |
| Irinoye, O | 1 |
| Ogun, SA | 1 |
| Odusoga, OL | 1 |
| Falola, OL | 1 |
| Muraina, HA | 1 |
| Rodríguez, C | 2 |
| Medici, M | 2 |
| Rodríguez, AV | 1 |
| Mozzi, F | 2 |
| Font de Valdez, G | 2 |
| Shi, Q | 1 |
| Li, MY | 1 |
| Vasanthkumar, M | 1 |
| Parameswari, RP | 1 |
| Vijaya Kumar, V | 1 |
| Sangeetha, MK | 1 |
| Gayathri, V | 1 |
| Balaji Raghavendran, H | 1 |
| Chamundeeswari, D | 1 |
| Vasanthi, HR | 1 |
| Peace, A | 1 |
| McCall, M | 1 |
| Tedesco, T | 1 |
| Kenny, D | 1 |
| Conroy, RM | 1 |
| Foley, D | 1 |
| Cox, D | 2 |
| Tian, Y | 1 |
| Ye, Y | 1 |
| Gao, W | 1 |
| Chen, H | 1 |
| Song, T | 1 |
| Wang, D | 1 |
| Mao, X | 1 |
| Ren, C | 1 |
| Sharpe, KS | 1 |
| Center, SA | 1 |
| Randolph, JF | 1 |
| Brooks, MB | 1 |
| Warner, KL | 1 |
| Stokol, T | 1 |
| Barr, SC | 1 |
| Felippe, MJ | 1 |
| Shen, L | 1 |
| Shen, J | 1 |
| Pu, J | 1 |
| He, B | 1 |
| Drazin, D | 1 |
| Choulakian, A | 1 |
| Nuño, M | 1 |
| Kornbluth, P | 1 |
| Alexander, MJ | 1 |
| Bhatt, LK | 1 |
| Addepalli, V | 1 |
| Mazya, M | 1 |
| Egido, JA | 1 |
| Ford, GA | 1 |
| Lees, KR | 1 |
| Mikulik, R | 1 |
| Toni, D | 1 |
| Wahlgren, N | 1 |
| Ahmed, N | 1 |
| Yu, Y | 1 |
| Li, B | 1 |
| Zhou, X | 1 |
| Niu, J | 1 |
| Wei, X | 1 |
| Wu, R | 3 |
| Yin, D | 1 |
| Sadekova, N | 1 |
| Deschepper, CF | 1 |
| de Champlain, J | 3 |
| Girouard, H | 1 |
| Rao, CV | 2 |
| Mohammed, A | 1 |
| Janakiram, NB | 1 |
| Li, Q | 1 |
| Ritchie, RL | 1 |
| Lightfoot, S | 1 |
| Vibhudutta, A | 1 |
| Steele, VE | 1 |
| Gurbel, PA | 1 |
| Erlinge, D | 1 |
| Ohman, EM | 1 |
| Neely, B | 1 |
| Neely, M | 1 |
| Goodman, SG | 1 |
| Huber, K | 1 |
| Chan, MY | 1 |
| Cornel, JH | 1 |
| Brown, E | 1 |
| Zhou, C | 1 |
| Jakubowski, JA | 1 |
| White, HD | 1 |
| Fox, KA | 1 |
| Prabhakaran, D | 1 |
| Armstrong, PW | 1 |
| Tantry, US | 1 |
| Roe, MT | 1 |
| El Midaoui, A | 1 |
| Mølck, AM | 1 |
| Poulsen, M | 1 |
| Meyer, O | 1 |
| Loneragan, GH | 1 |
| Morley, PS | 1 |
| Wagner, JJ | 1 |
| Mason, GL | 1 |
| Yost, GS | 1 |
| Thoren, MA | 1 |
| Wittum, TE | 1 |
| Bray, TM | 1 |
| Michel, C | 1 |
| Frankham, P | 1 |
| Cabanac, M | 1 |
| Dubey, K | 1 |
| Balani, DK | 1 |
| Pillai, KK | 1 |
| Gupta, U | 2 |
| Cook, JC | 2 |
| Tassinari, MS | 2 |
| Hurtt, ME | 2 |
| Cappon, GD | 1 |
| Tamminen, M | 1 |
| Lassila, R | 1 |
| Westerbacka, J | 1 |
| Vehkavaara, S | 1 |
| Yki-Järvinen, H | 1 |
| Hassan, SM | 1 |
| Mady, ME | 1 |
| Cartwright, AL | 1 |
| Sabri, HM | 1 |
| Mobarak, MS | 1 |
| LARSON, EJ | 1 |
| ANGERVALL, L | 1 |
| LEHMANN, L | 1 |
| BENGTSSON, U | 1 |
| FEINSTEIN, AR | 1 |
| AREVALO, AC | 1 |
| KLENSHOJ, NC | 1 |
| LOCKIE, LM | 1 |
| WINTER, JA | 1 |
| BARNESS, LA | 1 |
| YOUNG, LN | 1 |
| Williams, JL | 1 |
| Kashfi, K | 1 |
| Ouyang, N | 1 |
| del Soldato, P | 1 |
| Kopelovich, L | 1 |
| Rigas, B | 1 |
| Szalony, JA | 1 |
| Suleymanov, OD | 1 |
| Salyers, AK | 1 |
| Panzer-Knodle, SG | 1 |
| Blom, JD | 1 |
| LaChance, RM | 1 |
| Case, BL | 1 |
| Parlow, JJ | 1 |
| South, MS | 1 |
| Wood, RS | 1 |
| Nicholson, NS | 1 |
| Laplante, MA | 1 |
| Scranton, R | 1 |
| Sesso, HD | 1 |
| Stampfer, MJ | 1 |
| Levenson, JW | 1 |
| Buring, JE | 1 |
| Norflus, F | 1 |
| Nanje, A | 1 |
| Gutekunst, CA | 1 |
| Shi, G | 1 |
| Cohen, J | 1 |
| Bejarano, M | 1 |
| Fox, J | 1 |
| Ferrante, RJ | 1 |
| Hersch, SM | 1 |
| Burdan, F | 2 |
| Löbner, K | 1 |
| Füchtenbusch, M | 1 |
| Woodside, DB | 1 |
| Colton, P | 1 |
| Staab, R | 1 |
| Schreiber, M | 1 |
| Sutandar-Pinnock, K | 1 |
| Poynter, B | 1 |
| Sacevich, T | 1 |
| Maree, AO | 1 |
| Dooley, M | 1 |
| Conroy, R | 1 |
| Byrne, MF | 1 |
| Fitzgerald, DJ | 1 |
| Mei, ZR | 1 |
| Zheng, HL | 1 |
| Wu, HP | 1 |
| Zhu, XG | 1 |
| Payne, DA | 1 |
| Jones, CI | 1 |
| Hayes, PD | 1 |
| Naylor, AR | 1 |
| Goodall, AH | 1 |
| Nocun, M | 1 |
| Ulicna, O | 1 |
| Muchova, J | 1 |
| Durackova, Z | 1 |
| Watala, C | 1 |
| Zhang, Y | 1 |
| Miao, Y | 1 |
| Whitworth, JA | 2 |
| Jafarnejad, A | 1 |
| Bathaie, SZ | 1 |
| Nakhjavani, M | 1 |
| Hassan, MZ | 1 |
| Di Renzo, L | 1 |
| Noce, A | 1 |
| De Angelis, S | 1 |
| Miani, N | 1 |
| Di Daniele, N | 1 |
| Tozzo, C | 1 |
| De Lorenzo, A | 1 |
| Rosenthale, ME | 2 |
| Nagra, CL | 1 |
| Mason, RM | 1 |
| Barnardo, DE | 1 |
| Fox, WR | 1 |
| Weatherall, M | 1 |
| Burke, V | 1 |
| Gracey, M | 1 |
| Olazabal, A | 2 |
| Nascimento, L | 1 |
| Hashimoto, H | 1 |
| Ogawa, K | 1 |
| Prescott, LF | 1 |
| Balali-Mood, M | 1 |
| Critchley, JA | 1 |
| Johnstone, AF | 1 |
| Proudfoot, AT | 1 |
| Carlson, RP | 1 |
| Gilman, SC | 1 |
| Hodge, TG | 1 |
| O'Neill-Davis, L | 1 |
| Blazek, EM | 1 |
| Lewis, AJ | 1 |
| Lal, J | 1 |
| Meydani, SN | 1 |
| Meydani, M | 1 |
| Dupont, J | 1 |
| Akasaka, S | 1 |
| Iwagami, S | 1 |
| Harper, JA | 1 |
| Bernier, PE | 1 |
| Thompson-Cowley, LL | 1 |
| Mills, EH | 1 |
| Andrews, J | 1 |
| Kincaid-Smith, P | 1 |
| May, JD | 1 |
| McNaughton, JL | 1 |
| Ueno, K | 1 |
| Shimoto, Y | 1 |
| Yokoyama, A | 1 |
| Kitagawa, H | 1 |
| Takeno, S | 1 |
| Sakai, T | 1 |
| Saito, H | 1 |
| Runyan, TJ | 1 |
| Shayesteh, MR | 1 |
| Brooks, PM | 1 |
| Cossum, PA | 1 |
| Boyd, GW | 1 |
| Kato, Y | 1 |
| Senzaki, H | 1 |
| Ogura, H | 1 |
| Itami, T | 1 |
| Kanoh, S | 1 |
| Zimmermann, R | 1 |
| Thiessen, M | 1 |
| Walter, E | 1 |
| Mörl, H | 1 |
| Wong, DL | 1 |
| Pence, BC | 1 |
| Dunn, DM | 1 |
| Zhao, C | 1 |
| Landers, M | 1 |
| Wargovich, MJ | 1 |
| Marangos, MN | 1 |
| Onyeji, CO | 1 |
| Nicolau, DP | 1 |
| Nightingale, CH | 1 |
| Hamed, MR | 1 |
| al-Assy, YS | 1 |
| Ezzeldin, E | 1 |
| Rossi, F | 1 |
| Filippelli, W | 1 |
| Russo, S | 1 |
| Filippelli, A | 1 |
| Berrino, L | 1 |
| Mereto, E | 1 |
| Frencia, L | 1 |
| Ghia, M | 1 |
| Tessitore, L | 1 |
| Costelli, P | 1 |
| Baccino, FM | 1 |
| Berk, SI | 1 |
| Grunwald, A | 1 |
| Pal, S | 1 |
| Bodenheimer, MM | 1 |
| Reddy, BS | 1 |
| Rivenson, A | 1 |
| Kelloff, G | 1 |
| Murai, A | 1 |
| Furuse, M | 1 |
| Okumura, J | 1 |
| Kumar, H | 1 |
| Lehmann, H | 1 |
| Hirsch, U | 1 |
| Bauer, E | 1 |
| Bauer, M | 1 |
| Greischel, A | 1 |
| Schmid, J | 1 |
| Schneider, P | 1 |
| Kim, C | 1 |
| Nam, SW | 1 |
| Choi, DY | 1 |
| Choi, JH | 1 |
| Park, ES | 1 |
| Jhoo, WK | 1 |
| Kim, HC | 1 |
| Tantcheva, L | 1 |
| Stoytchev, T | 1 |
| Rangelova, D | 1 |
| Rioux, N | 1 |
| Castonguay, A | 1 |
| Ramesh, CV | 1 |
| Malarvannan, P | 1 |
| Jayakumar, R | 1 |
| Jayasundar, S | 1 |
| Puvanakrishnan, R | 1 |
| Lares-Asseff, I | 1 |
| Flores-Pérez, J | 1 |
| Juárez-Olguín, H | 1 |
| Ramírez-Lacayo, M | 1 |
| Loredo-Abdalá, A | 1 |
| Carbajal-Rodríguez, L | 1 |
| Barnéoud, P | 1 |
| Curet, O | 1 |
| Vitulli, WF | 1 |
| Kaiser, GA | 1 |
| Maranto, DL | 1 |
| Blake, SE | 1 |
| Storey, TM | 1 |
| McPherson, KP | 1 |
| Luper, SL | 1 |
| Witschi, H | 1 |
| Espiritu, I | 1 |
| Uyeminami, D | 1 |
| Milman, N | 1 |
| Ovesen, L | 1 |
| Byg, K | 1 |
| Graudal, N | 1 |
| Stahringer, RC | 1 |
| Neuendorff, DA | 1 |
| Randel, RD | 1 |
| Chiu, CH | 1 |
| McEntee, MF | 1 |
| Whelan, J | 1 |
| Cayatte, AJ | 1 |
| Du, Y | 1 |
| Oliver-Krasinski, J | 1 |
| Lavielle, G | 1 |
| Verbeuren, TJ | 1 |
| Cohen, RA | 1 |
| Balog, JM | 1 |
| Huff, GR | 1 |
| Rath, NC | 1 |
| Huff, WE | 1 |
| Paul, A | 1 |
| Calleja, L | 1 |
| Camps, J | 1 |
| Osada, J | 1 |
| Vilella, E | 1 |
| Ferré, N | 1 |
| Mayayo, E | 1 |
| Joven, J | 1 |
| Lambert, GP | 1 |
| Broussard, LJ | 1 |
| Mason, BL | 1 |
| Mauermann, WJ | 1 |
| Gisolfi, CV | 1 |
| Yu, XX | 1 |
| Odle, J | 1 |
| Drackley, JK | 1 |
| Matz, RL | 1 |
| Van Overloop, B | 1 |
| Gaubert, E | 1 |
| Gairard, A | 1 |
| Koch, HJ | 1 |
| Raschka, C | 1 |
| Jablonski, P | 1 |
| Howden, BO | 1 |
| Becker, RC | 1 |
| Spencer, FA | 1 |
| Gibson, M | 1 |
| Rush, JE | 1 |
| Sanderink, G | 1 |
| Murphy, SA | 1 |
| Ball, SP | 1 |
| Antman, EM | 1 |
| Bugat, R | 1 |
| Thompson, MR | 1 |
| Aures, D | 1 |
| Grossman, MI | 1 |
| Thomas, BH | 1 |
| Nera, EA | 1 |
| Zeitz, W | 1 |
| Alonso, S | 1 |
| Priego, J | 1 |
| Maroto, L | 1 |
| Ortega, P | 1 |
| Mendelson, J | 1 |
| Grisolia, S | 1 |
| Norby, L | 1 |
| Flamenbaum, W | 1 |
| Lentz, R | 1 |
| Ramwell, P | 1 |
| Hobbs, CL | 1 |
| Mullen, JL | 1 |
| Buzby, GP | 1 |
| Morrison, B | 1 |
| Rosato, EF | 1 |
| Gotoh, M | 2 |
| Griffin, C | 1 |
| Hruban, Z | 3 |
| Castracane, VD | 1 |
| Tankenow, LF | 1 |
| Shaikh, AA | 1 |
| Tanigawa, H | 1 |
| Obori, R | 1 |
| Tanaka, H | 1 |
| Yoshida, J | 1 |
| Kosazuma, T | 1 |
| Mäkela, AL | 1 |
| Yrjänä, T | 1 |
| Mattila, M | 1 |
| Done, AK | 1 |
| Yaffe, SJ | 1 |
| Clayton, JM | 1 |
| Sasaki, H | 1 |
| Woo, DC | 1 |
| McClain, RM | 1 |
| Hoar, RM | 1 |
| Levy, G | 1 |
| Giacomini, KM | 1 |
| Palm, PE | 1 |
| Arnold, EP | 1 |
| Rachwall, PC | 1 |
| Leyczek, JC | 1 |
| Teague, KW | 1 |
| Kensler, CJ | 1 |
| Molland, EA | 1 |
| Lubawy, WC | 1 |
| Garrett, RJ | 1 |
| Feurstein, V | 1 |
| Frenning, B | 1 |
| Johansson, H | 2 |
| Nilsson, F | 1 |
| Ohrn, PG | 1 |
| Beall, JR | 1 |
| Klein, MF | 1 |
| Shriver, DA | 2 |
| Dove, PA | 1 |
| White, CB | 1 |
| Sandor, A | 1 |
| Yates, CM | 1 |
| Wilson, H | 1 |
| Hial, V | 1 |
| Horakova, Z | 1 |
| Shaff, FE | 1 |
| Beaven, MA | 1 |
| DiPasquale, G | 1 |
| Rassaert, C | 1 |
| Welaj, P | 1 |
| Tripp, L | 1 |
| Tuchmann-Duplessis, H | 1 |
| Hiss, D | 1 |
| Mottot, G | 1 |
| Rosner, I | 1 |
| Awouters, F | 1 |
| Niemegeers, CJ | 1 |
| Lenaerts, FM | 1 |
| Janssen, PA | 1 |
| Chitwood, SJ | 1 |
| Goldman, M | 2 |
| Blum, SL | 1 |
| Graham, GG | 1 |
| Champion, GD | 1 |
| Hale, RL | 1 |
| Randall, CL | 2 |
| Becker, HC | 2 |
| Turner, KP | 1 |
| Johnson, AC | 1 |
| Kishore, V | 2 |
| Lush, DT | 1 |
| Anton, RF | 1 |
| Bauman, RA | 1 |
| Przybelski, RJ | 1 |
| Bounds, MJ | 1 |
| Burrell, JH | 1 |
| Yong, JL | 1 |
| Macdonald, GJ | 1 |
| Katz, LB | 1 |
| Homem-de-Bittencourt Júnior, PI | 1 |
| Pontieri, V | 1 |
| Curi, R | 1 |
| Lopes, OU | 1 |
| Mata-Segreda, JF | 1 |
| Fernández-Azofeifa, E | 1 |
| Madrigal, X | 1 |
| Morales, AC | 1 |
| Stilborn, HL | 1 |
| Harris, GC | 1 |
| Bottje, WG | 1 |
| Waldroup, PW | 1 |
| Moel, DI | 1 |
| Safirstein, RL | 1 |
| McEvoy, RC | 1 |
| Hsueh, W | 1 |
| Wilson, TW | 1 |
| McCauley, FA | 1 |
| Wells, HD | 1 |
| Sakata, T | 1 |
| Hasegawa, R | 1 |
| Johansson, SL | 1 |
| Zenser, TV | 1 |
| Cohen, SM | 1 |
| Greenblatt, DJ | 1 |
| Abernethy, DR | 1 |
| Boxenbaum, HG | 1 |
| Matlis, R | 1 |
| Ochs, HR | 1 |
| Harmatz, JS | 1 |
| Shader, RI | 1 |
| Owen, RA | 1 |
| Heywood, R | 1 |
| Assael, BM | 1 |
| Chiabrando, C | 1 |
| Gagliardi, L | 1 |
| Noseda, A | 1 |
| Bamonte, F | 1 |
| Salmona, M | 1 |
| Lindquist, B | 1 |
| Wilhelmi, G | 1 |
| Menassé-Gdynia, R | 1 |
| Sofia, RD | 2 |
| Vassar, HB | 1 |
| Nalepa, SD | 1 |
| Douglas, JF | 1 |
| Brühl, W | 1 |
| Swift, H | 1 |
| Slesers, A | 2 |
| Rukmono, B | 1 |
| Naumar, SA | 1 |
| Talogo, RW | 1 |
| Okabe, S | 1 |
| Takeuchi, K | 1 |
| Honda, K | 1 |
| Takagi, K | 1 |
| Kriegel, H | 1 |
| Lev, R | 1 |
| Siegel, HI | 1 |
| Glass, GB | 1 |
| Phillips, BM | 1 |
| Jacoby, HI | 1 |
| Marshall, CH | 1 |
| Zachariae, E | 1 |
| Sylvest, J | 1 |
| Axelsen, RA | 1 |
| Burry, AF | 1 |
| Beliles, RP | 1 |
| Poppens, CA | 1 |
| Gupta, N | 1 |
| Levy, L | 1 |
| Mackerer, CR | 1 |
| Mehlman, MA | 2 |
| Tobin, RB | 2 |
| Van Arman, CG | 1 |
| Nuss, GW | 1 |
| Risley, EA | 1 |
| Cohen, MM | 1 |
| Greenway, CV | 1 |
| Innes, IR | 1 |
| Lister, GE | 1 |
| Murthy, VS | 1 |
| Scott, GD | 1 |
| Hochschild, R | 1 |
| Chou, SF | 1 |
| Loew, D | 2 |
| Boehme, K | 1 |
| Artik, N | 1 |
| Wellmer, HK | 1 |
| Baer, U | 1 |
| Merguet, H | 1 |
| Rumpf, P | 1 |
| Petersen, H | 1 |
| Bromig, G | 1 |
| Persch, WF | 1 |
| Marx, FJ | 1 |
| von Bary, SM | 1 |
| Parkhouse, J | 1 |
| Rees-Lewis, M | 1 |
| Skolinik, M | 1 |
| Peters, H | 1 |
| Brocks, BE | 1 |
| Brazelton, TB | 1 |
| Glenn, EM | 1 |
| Rohloff, N | 1 |
| Dowdy, RP | 1 |
| Nielsen, FH | 1 |
| Walz, DT | 2 |
| DiMartino, MJ | 2 |
| Misher, A | 1 |
| Dolan, MM | 1 |
| Yankell, SL | 1 |
| Friedman, H | 1 |
| Coldwell, BB | 1 |
| Boyd, EM | 1 |
| Sasaki, S | 1 |
| Nakamura, H | 1 |
| Soji, Y | 1 |
| Masuda, Y | 1 |
| Nakamura, K | 1 |
| Madappally, MM | 1 |
| Hahn, HK | 1 |
| Shagrin, JW | 1 |
| Frame, B | 1 |
| Duncan, H | 1 |
| Laine, V | 1 |
| Strandman, D | 1 |
| Tikkanen, R | 1 |
| Paalzow, L | 1 |
| Limbeck, GA | 1 |
| Conger, JD | 1 |
| Tippit, DF | 1 |
| Kelley, VC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Enteric Coating as a Factor in Aspirin Resistance[NCT00531362] | 250 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
5 reviews available for aspirin and Body Weight
| Article | Year |
|---|---|
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardi | 2014 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arte | 2004 |
Coronary artery disease. The latest on prevention.
Topics: Animals; Antioxidants; Aspirin; Body Weight; Coronary Disease; Estrogens; Exercise; Fish Oils; Human | 1992 |
[Pathophysiological basis for the treatment of degenerative joint diseases].
Topics: Aspirin; Back Pain; Body Weight; Diagnosis, Differential; Humans; Mucopolysaccharidosis IV; Osteoart | 1973 |
Effect of prenatal drugs on the behavior of the neonate.
Topics: Aspirin; Barbiturates; Behavior; Body Weight; Depression, Chemical; Diet; Female; Fetus; Genotype; G | 1970 |
21 trials available for aspirin and Body Weight
| Article | Year |
|---|---|
Platelet inhibition by low-dose aspirin is not influenced by body mass or weight.
Topics: Adenosine Diphosphate; Adult; Arachidonic Acid; Aspirin; Blood Platelets; Body Weight; Collagen; Hum | 2022 |
Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study.
Topics: Adaptor Proteins, Signal Transducing; Adiposity; Adult; Anti-Inflammatory Agents, Non-Steroidal; Asp | 2015 |
Selenium and aspirin in people living with HIV and AIDS in Nigeria.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Aspirin; Black People; Body Weight; CD4 | 2008 |
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; F | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Weight; Cholesterol; | 2004 |
Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers.
Topics: Adult; Aspirin; Aspirin, Dipyridamole Drug Combination; Body Weight; Cross-Over Studies; Dipyridamol | 2006 |
Therapeutic benefit of low-dose clopidogrel in patients undergoing carotid surgery is linked to variability in the platelet adenosine diphosphate response and patients' weight.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Body Weight; Clopidogrel; Endarterectomy, Carotid; | 2007 |
Reduction by aspirin of intestinal fluid-loss in acute childhood gastroenteritis.
Topics: Aspirin; Bacterial Infections; Body Weight; Clinical Trials as Topic; Dehydration; Diarrhea, Infanti | 1980 |
Non-steroidal anti-inflammatory drugs and blood pressure.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Aspirin; Blood Pressure; Blood Pressure Determina | 1982 |
Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group.
Topics: Aspirin; Body Height; Body Weight; Canada; Cohort Studies; Developmental Disabilities; Double-Blind | 1995 |
Gastrointestinal permeability during exercise: effects of aspirin and energy-containing beverages.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Dietary Carbohydrates; Energy | 2001 |
Anthropometric data and acetylsalicylic acid pharmacokinetics.
Topics: Adult; Anthropometry; Area Under Curve; Aspirin; Body Height; Body Mass Index; Body Surface Area; Bo | 2002 |
Dosage of salicylates for children with juvenile rheumatoid arthritis. A prospective clinical trial with three different preparations of acetylsalicylic acid.
Topics: Adolescent; Arthritis; Arthritis, Juvenile; Aspartate Aminotransferases; Aspirin; Benzidines; Body W | 1979 |
Effects of low-dose aspirin on responses to furosemide.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Blood Platelets; Body Weight; Eicosanoic Acids; Electr | 1986 |
Osteoarthritis of the knee treated with tolfenamic acid.
Topics: Adult; Aged; Alanine Transaminase; Aspirin; Body Weight; Clinical Trials as Topic; Creatinine; Femal | 1972 |
[A model for studying the antithrombotic effect of acetylsalicylic acid in the prevention of postoperative thrombo-embolism (author's transl)].
Topics: Age Factors; Anticoagulants; Aspirin; Blood Coagulation Disorders; Body Weight; Female; Humans; Male | 1974 |
[Prevention of postoperative thrombo-embolism with acetylsalicyclic acid (author's transl)].
Topics: Age Factors; Angina Pectoris; Aspirin; Body Weight; Diabetes Complications; Female; Follow-Up Studie | 1974 |
The clinical dose response to aspirin.
Topics: Age Factors; Analgesia; Aspirin; Body Weight; Clinical Trials as Topic; Diet; Female; Humans; Male; | 1968 |
A comparison of flufenamic acid and phenylbutazone in osteoarthritis of the hip.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Blood Sedimentation; Body Weight; Clinical Trials as Topic; | 1966 |
Clinical trials of ibuprofen in Japan. Report from the Drug Evaluation Committee, the official organ of the Japan Rheumatism Association.
Topics: Adult; Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzyl | 1970 |
193 other studies available for aspirin and Body Weight
| Article | Year |
|---|---|
Synthesis and anti-inflammatory activity of 2-aryloxy methyl oxazolines.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Chemistry, Pharmaceutical; Drug Design; Edema; Ethan | 2008 |
Effect of body weight on bleeding events of aspirin in ischemic stroke or transient ischemic attack patients.
Topics: Aspirin; Body Weight; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, T | 2022 |
Aspirin attenuates the expression of adhesion molecules, risk of obesity, and adipose tissue inflammation in high-fat diet-induced obese mice.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Aspirin; Blood Glucose; Body Weight; Diet, High-F | 2022 |
Adjusting the dose in paediatric care by dispersing fragments of four different aspirin tablets.
Topics: Aspirin; Body Weight; Child; Drug Compounding; Humans; Tablets | 2020 |
No Modulation of the Effect of Aspirin by Body Weight in Healthy Older Men and Women.
Topics: Age Factors; Aging; Aspirin; Body Weight; Female; Humans; Male | 2020 |
Body weight, CYP2C19, and P2Y12 receptor polymorphisms relate to clopidogrel resistance in a cohort of Chinese ischemic stroke patients with aspirin intolerance.
Topics: Aged; Aspirin; Body Weight; Clopidogrel; Cohort Studies; Cytochrome P-450 CYP2C19; Drug Resistance; | 2020 |
Use of aspirin to intentionally induce gastrointestinal tract barrier dysfunction in feedlot cattle.
Topics: Animals; Aspirin; Biomarkers; Body Weight; Cattle; Cattle Diseases; Chromium; Diet; Digestion; Femal | 2020 |
Low-dose aspirin was associated with an increased risk of cardiovascular events in patients with chronic kidney disease patients and low bodyweight: results from KNOW-CKD study.
Topics: Aspirin; Body Weight; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Kidney Function T | 2021 |
Analgesic Activity of Jin Ling Zi Powder and Its Single Herbs: A Serum Metabonomics Study.
Topics: Analgesics; Animals; Aspirin; Biomarkers; Body Weight; Drugs, Chinese Herbal; Glycine; Glyoxylates; | 2022 |
The Protective Effect of Aspirin against Myocardial Hypertrophy in Rats.
Topics: Animals; Apoptosis; Aspirin; Blood Pressure; Body Weight; Cardiotonic Agents; Disease Models, Animal | 2021 |
Platelet testing to guide aspirin dose adjustment in pediatric patients after cardiac surgery.
Topics: Aspirin; Body Weight; Cardiac Surgical Procedures; Chemoprevention; Child, Preschool; Dose-Response | 2017 |
Effect of Low-Dose Aspirin on Chronic Acid Reflux Esophagitis in Rats.
Topics: Administration, Oral; Animals; Aspirin; Body Weight; Chronic Disease; Dose-Response Relationship, Dr | 2018 |
Feces and liver tissue metabonomics studies on the regulatory effect of aspirin eugenol eater in hyperlipidemic rats.
Topics: Administration, Oral; Amino Acids; Animals; Aspirin; Bile Acids and Salts; Body Weight; Cholesterol, | 2017 |
Use of acetylsalicylic acid as an allostatic modulator in the diets of growing Japanese quails exposed to heat stress.
Topics: Allosteric Regulation; Animals; Aspirin; Body Weight; Coturnix; Diet; Dietary Supplements; Heat-Shoc | 2018 |
Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.
Topics: Age Factors; Aged; Aspirin; Body Height; Body Weight; Cardiovascular Diseases; Colorectal Neoplasms; | 2018 |
Time to adjust aspirin dose to body weight.
Topics: Aspirin; Body Weight; Humans; Neoplasms | 2018 |
Metabolism of liver CYP450 and ultrastructural changes after long-term administration of aspirin and ibuprofen.
Topics: Animals; Aspirin; Body Weight; Cytochrome P-450 Enzyme System; Discriminant Analysis; Ibuprofen; Liv | 2018 |
Sex-associated preventive effects of low-dose aspirin on obesity and non-alcoholic fatty liver disease in mouse offspring with over-nutrition in utero.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Diet, High-Fat; Female; Gluc | 2019 |
Pooled RCTs: Low-dose ASA reduced CV events in persons < 70 kg; higher-dose ASA was effective at higher body weights.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Humans; Neoplasms; Platelet Aggregati | 2018 |
[Weight-dependent dosing of aspirin; the pharmacological and cardiological perspective].
Topics: Aspirin; Body Weight; Cardiology; Humans; Neoplasms; Primary Prevention | 2018 |
Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspirin and low-dose diethylstilbestrol.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Weight; Bone and Bones; | 2013 |
Combining aspirin with cholecalciferol (vitamin D3)--a potential new tool for controlling possum populations.
Topics: Animals; Aspirin; Body Weight; Cholecalciferol; Drug Synergism; Female; Gastrointestinal Tract; Intr | 2013 |
The effect of melatonin on acetylsalicylic acid-induced kidney and testis damage.
Topics: Animals; Aspirin; Blood Urea Nitrogen; Body Weight; Catalase; Creatine; Glutathione; Glutathione Per | 2014 |
Low-dose aspirin ameliorated hyperlipidemia, adhesion molecule, and chemokine production induced by high-fat diet in Sprague-Dawley rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Aspirin; Atherosclerosis; Blood P | 2014 |
Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.
Topics: Animals; Apoptosis; Aromatase; Aspirin; Body Weight; Breast Neoplasms; Celecoxib; Cell Cycle; Cycloo | 2014 |
Egg production response of laying chickens to feather clipping, cool water and aspirin during hot weather conditions.
Topics: Animal Husbandry; Animals; Antipyretics; Aspirin; Body Weight; Chickens; Climate; Drinking Behavior; | 2014 |
Rebamipide Promotes the Regeneration of Aspirin-Induced Small-Intestine Mucosal Injury through Accumulation of β-Catenin.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; beta Catenin; Body Weight; Cell | 2015 |
Enhanced Glucose Tolerance and Pancreatic Beta Cell Function by Low Dose Aspirin in Hyperglycemic Insulin-Resistant Type 2 Diabetic Goto-Kakizaki (GK) Rats.
Topics: Animals; Aspirin; Body Weight; Diabetes Mellitus, Type 2; Dinoprostone; Dose-Response Relationship, | 2015 |
Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice.
Topics: Administration, Oral; Animals; Aspirin; Body Weight; Chitosan; Curcumin; Drug Liberation; Female; Is | 2016 |
Aspirin prevents bone loss with little mechanical improvement in high-fat-fed ovariectomized rats.
Topics: Animals; Aspirin; Biomarkers; Biomechanical Phenomena; Body Weight; Bone Density; Diet, High-Fat; Fe | 2016 |
Effect of chronic aspirin administration on an experimental model of metabolic syndrome.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Aspirin; Blood Glucose; Blood Pressure; Bod | 2009 |
Effect of carnosine, aminoguanidine, and aspirin drops on the prevention of cataracts in diabetic rats.
Topics: Animals; Aspirin; Blood Glucose; Body Weight; Carnosine; Cataract; Cornea; Diabetes Mellitus, Experi | 2008 |
Prevention of chronic gastritis by fermented milks made with exopolysaccharide-producing Streptococcus thermophilus strains.
Topics: Animals; Aspirin; Body Weight; Chronic Disease; Cultured Milk Products; Cyclooxygenase Inhibitors; G | 2009 |
Effect of a combination of carnosine and aspirin eye drops on streptozotocin -- induced diabetic cataract in rats.
Topics: Animals; Aspirin; Blood Glucose; Body Weight; Carnosine; Cataract; Diabetes Complications; Drinking | 2009 |
Anti-ulcer role of herbomineral Siddha drug - Thamira parpam on experimentally induced gastric mucosal damage in rats.
Topics: Animals; Anti-Ulcer Agents; Antioxidants; Aspirin; Body Weight; Cytoprotection; Disease Models, Anim | 2010 |
Therapeutic effect of Streptococcus thermophilus CRL 1190-fermented milk on chronic gastritis.
Topics: Animals; Aspirin; Body Weight; Fermentation; Gastric Mucosa; Gastritis; Inflammation; Interferon-gam | 2010 |
The role of weight and enteric coating on aspirin response in cardiovascular patients.
Topics: Aged; Aspirin; Body Weight; Cardiology; Cardiovascular Diseases; Humans; Middle Aged; Patient Compli | 2010 |
Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway.
Topics: Animals; Apoptosis; Aspirin; bcl-X Protein; Body Weight; Colorectal Neoplasms; Disease Models, Anima | 2011 |
Influence of treatment with ultralow-dose aspirin on platelet aggregation as measured by whole blood impedance aggregometry and platelet P-selectin expression in clinically normal dogs.
Topics: Adenosine Diphosphate; Animals; Aspirin; Blood Platelets; Body Composition; Body Weight; Dogs; Dose- | 2010 |
Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels.
Topics: Animals; Aspirin; Blood Pressure; Body Weight; Disease Models, Animal; Heart Rate; Hemodynamics; Hyp | 2011 |
Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting.
Topics: Aspirin; Body Mass Index; Body Weight; Carotid Stenosis; Cerebrovascular Disorders; Clopidogrel; Fem | 2011 |
Potentiation of aspirin-induced cerebroprotection by minocycline: a therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia.
Topics: Animals; Aspirin; Blood Glucose; Blood-Brain Barrier; Body Weight; Brain; Brain Edema; Capillary Per | 2012 |
A 15-day oral dose toxicity study of aspirin eugenol ester in Wistar rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Aspirin; Bilirubin | 2012 |
Protective effects of aspirin from cardiac hypertrophy and oxidative stress in cardiomyopathic hamsters.
Topics: Animals; Aorta; Aspirin; Blood Pressure; Body Weight; Cardiomegaly; Cardiomyopathies; Cardiotonic Ag | 2012 |
Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice.
Topics: Animals; Anticarcinogenic Agents; Aspirin; beta Catenin; Body Weight; Carcinoma in Situ; Carcinoma, | 2012 |
Prevention of hypertension, hyperglycemia and vascular oxidative stress by aspirin treatment in chronically glucose-fed rats.
Topics: Animals; Aorta; Aspirin; Blood Glucose; Blood Pressure; Body Weight; Canada; Cyclooxygenase Inhibito | 2002 |
The combination of 1alpha,25(OH2)-vitamin D3, calcium and acetylsalicylic acid affects azoxymethane-induced aberrant crypt foci and colorectal tumours in rats.
Topics: Animals; Aspirin; Azoxymethane; Body Weight; Calcitriol; Calcium; Colorectal Neoplasms; Dose-Respons | 2002 |
Effects of feeding aspirin and supplemental vitamin E on plasma concentrations of 3-methylindole, 3-methyleneindolenine-adduct concentrations in blood and pulmonary tissues, lung lesions, and growth performance in feedlot cattle.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Cattle; Cattle Diseases; Die | 2002 |
Salicylate as a partial inhibitor of emotional fever and body weight set-point in rats: behavioral and neuroendocrine study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Temperature; Body Weight; Corticotro | 2003 |
Potential adverse interaction between aspirin and lisinopril in hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Blood Pressure; Body Weight; Drug Antago | 2003 |
Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; | 2003 |
Comparison of the developmental toxicity of aspirin in rabbits when administered throughout organogenesis or during sensitive windows of development.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; | 2003 |
Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.
Topics: Adenosine Diphosphate; Analysis of Variance; Arachidonic Acid; Arteriosclerosis; Aspirin; Blood Gluc | 2003 |
Effect of acetyl salicylic acid in drinking water on reproductive performance of Japanese quail (Coturnix coturnix japonica).
Topics: Animals; Aspirin; Body Weight; Coturnix; Drinking; Female; Fertility; Genitalia, Female; Hot Tempera | 2003 |
TOXICITY OF LOW DOSES OF ASPIRIN IN THE CAT.
Topics: Anemia; Animals; Aspirin; Body Weight; Cats; Chemical and Drug Induced Liver Injury; Erythrocyte Cou | 1963 |
THE RENAL CONCENTRATING CAPACITY IN ALBINO RATS AFTER LONG-TERM CONSUMPTION OF PHENACETIN, NAPA (N-ACETYL-P-AMINOPHENOL) AND ACETYLSALICYLIC ACID.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Body Weight; Erythrocyte | 1964 |
MANIFESTATIONS AND TREATMENT OF CONGESTIVE HEART FAILURE IN YOUNG PATIENTS WITH RHEUMATIC HEART DISEASE.
Topics: Adolescent; Aspirin; Body Weight; Child; Diagnosis; Diet, Sodium-Restricted; Digitalis Glycosides; D | 1964 |
A CLINICAL APPRAISAL OF A NEW EFFECTIVE SUSTAINED RELEASE ASPIRIN TABLET.
Topics: Analgesia; Aspirin; Biomedical Research; Blood; Body Weight; Delayed-Action Preparations; Drug Thera | 1964 |
A SIMPLIFIED VIEW OF FLUID THERAPY.
Topics: Acidosis; Adrenal Insufficiency; Anuria; Aspirin; Body Weight; Burns; Calcium; Child; Cystic Fibrosi | 1964 |
NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Body Weight; Cel | 2004 |
Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.
Topics: Animals; Aspirin; Bleeding Time; Body Weight; Disease Models, Animal; Factor VIIa; Macaca fascicular | 2003 |
Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Antioxidants; Aorta; Aspirin; Body Weight; Cells, | 2004 |
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice.
Topics: Acoustic Stimulation; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; As | 2004 |
Developmental toxicity evaluation of ibuprofen and tolmetin administered in triple daily doses to Wistar CRL:(WI)WUBR rats.
Topics: Animals; Aspirin; Body Weight; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Female; | 2004 |
Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.
Topics: Abdominal Wall; Abnormalities, Drug-Induced; Alanine Transaminase; Animals; Aspartate Aminotransfera | 2005 |
Weight restoration in a patient with anorexia nervosa on dialysis.
Topics: Adult; Anorexia Nervosa; Aspirin; Barbiturates; Body Mass Index; Body Weight; Caffeine; Combined Mod | 2005 |
[Inhibitory effects of Aspisol on growth of transplanted breast cancer in C3H mice].
Topics: Animals; Apoptosis; Aspirin; Body Weight; Caspase 3; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Fe | 2006 |
French maritime pine bark extract Pycnogenol reduces thromboxane generation in blood from diabetic male rats.
Topics: Animals; Aspirin; Blood Glucose; Body Weight; C-Peptide; Cyclooxygenase Inhibitors; Diabetes Mellitu | 2008 |
Aspirin prevents and partially reverses adrenocorticotropic hormone-induced hypertension in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressu | 2007 |
Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats.
Topics: Animals; Aspirin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Ty | 2008 |
How to lower your risk for colon cancer. The search for answers circles back to some familiar recommendations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Body Weight; Calcium, Die | 2007 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastati | 2008 |
Comparative effects of some immunosuppressive and anti-inflammotory drugs on allergic encephalomyelitis and adjuvant arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Blood Cell Count; Body Weight; Cortisone; Enc | 1967 |
Assessment of drugs in out-patients with rheumatoid arthritis. Evaluation of methods and a comparison of mefenamic and flufenamic acids with phenylbutazone and aspirin.
Topics: Acetaminophen; Adult; Agglutination Tests; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; | 1967 |
Effects of indomethacin, aspirin, and fat-free diet on experimental pancreatitis in the rat.
Topics: Amylases; Animals; Aspirin; Body Weight; Deoxycholic Acid; Dietary Fats; Female; Indomethacin; Pancr | 1980 |
Effects of sulfinpyrazone, aspirin and propranolol on the isoproterenol-induced myocardial necrosis.
Topics: Animals; Aspirin; Body Weight; Creatine Kinase; Cyclic AMP; Heart; Isoproterenol; Male; Myocardial I | 1981 |
Diuresis or urinary alkalinisation for salicylate poisoning?
Topics: Adolescent; Adult; Aged; Aspirin; Bicarbonates; Body Weight; Diuretics; Female; Humans; Hydrogen-Ion | 1982 |
Effects of oral aspirin and oxaprozin on the development of lupus-like disease in MRL/1 mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Antibodies, Anti-Idiotypic; Aspirin; Autoim | 1984 |
Possible role of prostaglandins in the regulation of food intake in the newborn rat.
Topics: Animals; Animals, Newborn; Animals, Suckling; Aspirin; Body Weight; Dinoprost; Dinoprostone; Eating; | 1984 |
Effects of prostaglandin modifiers and zinc deficiency on possibly related functions in rats.
Topics: Alkaline Phosphatase; Animals; Aspirin; Body Weight; Immunity, Cellular; Indomethacin; Interleukin-2 | 1983 |
[Estimation of drug-metabolizing enzyme activities by measuring urinary metabolites of aspirin].
Topics: Animals; Aspirin; Biotransformation; Body Weight; Cytochrome P-450 Enzyme System; Gentisates; Male; | 1983 |
Early expression of hereditary deep pectoral myopathy in turkeys due to forced wing exercise.
Topics: Age Factors; Animals; Aspirin; Body Weight; Crosses, Genetic; Female; Food Additives; Male; Muscular | 1983 |
Effects of dietary ascorbic acid, aspirin, lysine, and thiouracil on thyroid activity.
Topics: Animals; Ascorbic Acid; Aspirin; Body Weight; Chickens; Diet; Lysine; Organ Size; Thiouracil; Thyroi | 1980 |
Alleviation of acetylsalicylic acid-induced fetal toxicity by calcium.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Body Weight; Calcium; Calcium Chloride; Drug Antagoni | 1983 |
Isoproterenol-induced mortality and cardiac lipids of aspirin-pretreated rats with various fat intakes.
Topics: Animals; Aspirin; Body Weight; Dietary Fats; Drug Interactions; Fatty Acids, Essential; Female; Hear | 1983 |
Rebound rise in renin concentrations after cessation of salicylates.
Topics: Aspirin; Blood Pressure; Body Weight; Humans; Renin; Salicylates; Time Factors | 1980 |
Aspirin-induced hypocalcemia in the rat.
Topics: Adrenalectomy; Animals; Aspirin; Body Weight; Calcium; Hypocalcemia; Indomethacin; Male; Nephrectomy | 1982 |
[Studies on the pharmacological bases of fetal toxicity of drugs. (I). Relation of fetal toxicity and tissue concentration of acetylsalicylic acid with pyrogen in pregnant rats].
Topics: Abnormalities, Drug-Induced; Adenosine Triphosphate; Animals; Aspirin; Body Weight; Drug Synergism; | 1982 |
Paradoxical effect of high and low dose aspirin in experimental arterial thrombosis.
Topics: Animals; Aorta, Abdominal; Arteries; Aspirin; Blood Coagulation; Body Weight; Dose-Response Relation | 1980 |
Dosage of aspirin.
Topics: Age Factors; Aspirin; Body Weight; Child; Child, Preschool; Humans; Infant | 1980 |
Chemopreventive effects of calcium but not aspirin supplementation in cholic acid-promoted colon carcinogenesis: correlation with intermediate endpoints.
Topics: Animals; Anticarcinogenic Agents; Aspirin; Azoxymethane; Biomarkers, Tumor; Body Weight; Calcium; Ch | 1995 |
Disposition kinetics of aspirin in female New Zealand white rabbits.
Topics: Animals; Aspirin; Body Weight; Chromatography, High Pressure Liquid; Female; Kinetics; Rabbits; Sali | 1995 |
Influence of protein malnutrition on teratogenicity of acetylsalicylic acid in rats.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Aspirin; Body Weight; Bone and Bones; Ca | 1994 |
Cardiotoxicity of doxorubicin: effects of drugs inhibiting the release of vasoactive substances.
Topics: Animals; Aspirin; Body Weight; Calcium; Cardiomyopathies; Catecholamines; Cromolyn Sodium; Doxorubic | 1994 |
Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine.
Topics: 1,2-Dimethylhydrazine; Animals; Anticarcinogenic Agents; Aspirin; Body Weight; Carcinogens; Cell Div | 1994 |
Pharmacological interference with tissue hypercatabolism in tumour-bearing rats.
Topics: Adrenalectomy; Animals; Aspirin; Blood Glucose; Body Weight; Cachexia; Cathepsin D; Cholesterol; End | 1994 |
Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease.
Topics: Aged; Analysis of Variance; Aspirin; Body Weight; Coronary Disease; Female; Heparin; Humans; Infusio | 1993 |
Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats.
Topics: Adenocarcinoma; Adenoma; Animals; Anticarcinogenic Agents; Aspirin; Azoxymethane; Body Weight; Colon | 1993 |
Involvement of (n-6) essential fatty acids and prostaglandins in liver lipid accumulation in Japanese quail.
Topics: Animals; Aspirin; Body Weight; Coturnix; Dietary Fats; Dinoprost; Fatty Acids, Essential; Fatty Acid | 1996 |
Dose of prophylactic aspirin in IHD and body weight.
Topics: Aspirin; Body Weight; Dose-Response Relationship, Drug; Humans; Myocardial Ischemia; Platelet Aggreg | 1995 |
Studies on the chronic oral toxicity of an analgesic drug combination consisting of acetylsalicylic acid, paracetamol and caffeine in rats including an electron microscopical evaluation of kidneys.
Topics: Acetaminophen; Analgesics; Animals; Aspirin; Blood Cell Count; Body Weight; Caffeine; Central Nervou | 1996 |
A new antithrombotic agent, aspalatone, attenuated cardiotoxicity induced by doxorubicin in the mouse; possible involvement of antioxidant mechanism.
Topics: Animals; Antibiotics, Antineoplastic; Aspirin; Body Weight; Doxorubicin; Fibrinolytic Agents; Glutat | 1997 |
Influence of hydrocortisone on the analgesic effect, toxicity and metabolism of aspirin in mice.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bleeding Time; | 1997 |
Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents.
Topics: Animals; Anticarcinogenic Agents; Arachidonic Acid; Aspirin; Body Weight; Carcinogens; Drug Screenin | 1998 |
Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis.
Topics: Adrenergic beta-Agonists; Animals; Aspirin; Body Weight; Creatine Kinase; Disease Models, Animal; Fe | 1998 |
Influence of nutritional status on the pharmacokinetics of acetylsalicylic acid and its metabolites in children with autoimmune disease.
Topics: Adolescent; Anthropometry; Area Under Curve; Aspirin; Autoimmune Diseases; Biotransformation; Body W | 1999 |
Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on motor performance in a transgenic model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weigh | 1999 |
Acetaminophen effects on behavioral thermoregulation in albino rats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1999 |
Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Atmosphere Exposure Chambers; Body Weight; Chemopreventi | 1999 |
Iron status in Danes updated 1994. I: prevalence of iron deficiency and iron overload in 1332 men aged 40-70 years. Influence Of blood donation, alcohol intake, and iron supplementation.
Topics: Adult; Aged; Alcohol Drinking; Anemia, Iron-Deficiency; Antacids; Aspirin; Blood Donors; Body Weight | 1999 |
The effect of aspirin administration and parity on plasma salicylate concentrations and postpartum reproductive parameters in Brahman cows.
Topics: Animals; Aspirin; Body Weight; Cattle; Dinoprost; Estrus; Female; Parity; Postpartum Period; Pregnan | 1999 |
Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc(Min/+)mice.
Topics: 6-Ketoprostaglandin F1 alpha; Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Ste | 2000 |
The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Aorta; Apolipoproteins | 2000 |
Effect of dietary aspirin on ascites in broilers raised in a hypobaric chamber.
Topics: Altitude; Animal Nutritional Physiological Phenomena; Animals; Ascites; Aspirin; Atmospheric Pressur | 2000 |
The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Aspirin; Body Weight; Iron; Lipids; Lipoproteins; Mice | 2000 |
Differential induction of peroxisomal beta-oxidation enzymes by clofibric acid and aspirin in piglet tissues.
Topics: Acyl-CoA Oxidase; Animals; Animals, Newborn; Aspirin; Body Weight; Carnitine O-Palmitoyltransferase; | 2001 |
Maturation reveals a decrease in endothelium-dependent contraction induced by depolarization in the aorta of spontaneously hypertensive rats.
Topics: Aging; Animals; Aorta; Aspirin; Biphenyl Compounds; Body Weight; Endothelium, Vascular; Heptanoic Ac | 2001 |
Oral buprenorphine and aspirin analgesia in rats undergoing liver transplantation.
Topics: Activity Cycles; Administration, Oral; Analgesics, Opioid; Animals; Aspirin; Body Weight; Buprenorph | 2002 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
Gastric mucosal lesions produced by intravenous infusion of aspirin in cats.
Topics: Animals; Aspirin; Body Weight; Cats; Dose-Response Relationship, Drug; Female; Gastric Mucosa; Hydro | 1976 |
Failure to observe pathology in the rat following chronic dosing with acetaminophen and acetylsalicylic acid.
Topics: Acetaminophen; Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Asp | 1977 |
[Comparative study of acute and chronic toxicity of etherilate, benorylate and acetylsalicylic acid].
Topics: Acetanilides; Animals; Aspirin; Blood Coagulation; Body Weight; Liver; Male; Mice; Rats; Salicylates | 1978 |
Letter: Age-dependent sensitivity to salicylate.
Topics: Adult; Age Factors; Animals; Aspirin; Body Weight; Child; Drug Hypersensitivity; Humans; Mice; Rats | 1975 |
Prostaglandins and aspirin therapy in Bartter's syndrome.
Topics: Aldosterone; Aspirin; Bartter Syndrome; Body Weight; Female; Humans; Hyperaldosteronism; Infant; Pot | 1976 |
The effects of nutrition on aspirin-induced mucosal ulceration in primates.
Topics: Animals; Aspirin; Body Weight; Diet; Gastric Acidity Determination; Haplorhini; Macaca; Male; Nitrog | 1979 |
Effect of citrate and aminotriazole on matrical plates induced in hepatic microbodies.
Topics: Amitrole; Animals; Aspirin; Body Weight; Carboxylic Acids; Catalase; Citrates; Clofibrate; Cycloprop | 1975 |
The effect of inhibition of prostaglandin synthesis on ovarian hypertrophy in the rat.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Animals; Aspirin; Body Weight; Castration; Female; Gona | 1975 |
[Reproduction study of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101) in rabbits. Administration of M73101 during the period of major organogenesis (author's transl)].
Topics: Abnormalities, Drug-Induced; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; | 1979 |
Aspirin dosage for infants and children.
Topics: Age Factors; Aspirin; Body Surface Area; Body Weight; Child; Child, Preschool; Drug Administration S | 1979 |
[A clinical study of pathophysiological feature of "Bartter's syndrome" (author's transl)].
Topics: Adult; Angiotensin II; Aspirin; Bartter Syndrome; Blood Pressure; Body Weight; Diet, Sodium-Restrict | 1979 |
Potentiation of methotrexate embryolethality by aspirin in rats.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Body Weight; Drug Synergism; Embryo, Mammalian; Femal | 1978 |
Rational aspirin dosage regimens.
Topics: Adult; Aspirin; Body Weight; Drug Administration Schedule; Female; Humans; Kinetics; Male; Models, B | 1978 |
Evaluation of the teratogenic potential of fresh-brewed coffee and caffeine in the rat.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Body Weight; Caffeine; Coffee; Cricetinae; Female; Le | 1978 |
Experimental renal papillary necrosis.
Topics: Acetaminophen; Animals; Aspirin; Body Weight; Drug Combinations; Female; Kidney Cortex; Kidney Medul | 1978 |
Effects of aspirin and acetaminophen on fetal and placental growth in rats.
Topics: Acetaminophen; Animals; Aspirin; Body Weight; Female; Fetus; Placenta; Pregnancy; Rats | 1977 |
[Pain suppression in childhood].
Topics: Age Factors; Aminopyrine; Analgesics; Aspirin; Body Weight; Child, Preschool; Headache; Humans; Infa | 1977 |
Acetylsalicyclic acid and gastrointestinal propulsion in the rat.
Topics: Animals; Aspirin; Body Weight; Duodenum; Gastrointestinal Motility; Hydrochloric Acid; Male; Rats; S | 1977 |
Enhancement of aspirin-induced teratogenicity by food restriction in rats.
Topics: Abnormalities, Drug-Induced; Animals; Aspirin; Body Weight; Female; Food Deprivation; Maternal-Fetal | 1977 |
A profile of the gastrointestinal toxicity of aspirin, indomethacin, oxaprozin, phenylbutazone, and fentiazac in arthritic and Lewis normal rats.
Topics: Acetates; Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Aspirin; Body Weigh | 1977 |
Effect of chlorpromazine and acetylsalicylic acid in vivo on lysosomal enzymes in rat brain.
Topics: Acid Phosphatase; Animals; Arylsulfatases; Aspirin; Body Weight; Cerebral Cortex; Chlorpromazine; Co | 1976 |
Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse.
Topics: Animals; Aspirin; Body Weight; Cell Count; Histamine; Histidine Decarboxylase; Indomethacin; Mice; M | 1976 |
Anti-inflammatory activity of isoxicam in combination with aspirin or D-propoxyphene.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Aspirin; Body Weight; Dextropropoxyphene | 1976 |
Effects of prenatal administration of acetylsalicylic acid in rats.
Topics: Animals; Animals, Newborn; Aspirin; Behavior, Animal; Body Weight; Female; Fetal Death; Pregnancy; P | 1975 |
The effects of suprofen in rats with Mycobacterium butyricum-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Biometry; Body Weight; Bone and B | 1975 |
Effect of aspirin on adrenal weight in female rats.
Topics: Adrenal Glands; Animals; Aspirin; Body Weight; Depression, Chemical; Female; Organ Size; Ovary; Pitu | 1976 |
Letter: Correlation of plateau serum salicylate with rate of salicylate metabolism.
Topics: Aspirin; Body Weight; Humans; Kinetics; Salicylates | 1976 |
Aspirin pretreatment reduces ethanol withdrawal severity in a mouse model of binge drinking.
Topics: Alcoholism; Animals; Aspirin; Body Weight; Disease Models, Animal; Ethanol; Male; Mice; Mice, Inbred | 1992 |
Auditory sensitivity in rats exposed to toluene and/or acetyl salicylic acid.
Topics: Acoustic Stimulation; Animals; Aspirin; Body Weight; Drug Synergism; Evoked Potentials, Auditory, Br | 1992 |
Effects of copper aspirinate and aspirin on tissue copper, zinc, and iron concentrations following chronic oral treatment in the adjuvant arthritic rat.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Aspirin; Body Weight; Copper; Dose-Response | 1990 |
Effect of ibuprofen on alcohol-induced teratogenesis in mice.
Topics: Abnormalities, Drug-Induced; Analysis of Variance; Animals; Aspirin; Body Weight; Ethanol; Female; F | 1991 |
The effects of alpha-alpha cross-linked hemoglobin on the feeding and locomotor activity of rats.
Topics: Animals; Appetitive Behavior; Aspirin; Blood Substitutes; Body Weight; Circadian Rhythm; Cross-Linki | 1991 |
Experimental analgesic nephropathy: changes in renal structure and urinary concentrating ability in Fischer 344 rats given continuous low doses of aspirin and paracetamol.
Topics: Acetaminophen; Animals; Aspirin; Body Weight; Disease Models, Animal; Female; Kidney Concentrating A | 1990 |
Rioprostil heals pre-existing aspirin-induced gastric lesions in dogs during daily aspirin administration without altering the anti-inflammatory or analgesic efficacy of aspirin.
Topics: Analgesia; Animals; Anti-Ulcer Agents; Aspirin; Body Weight; Dinoprostone; Dogs; Female; Gastric Muc | 1989 |
Effects of aspirin-like drugs on Walker 256 tumor growth and cachexia in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Weight; Cachexia; Carcinoma 256, Wal | 1989 |
Clinical evaluation of acetylsalicylic acid to improve glycemia in type II diabetic patients.
Topics: Adult; Aged; Aspirin; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Insulin | 1989 |
Ascorbic acid and acetylsalicylic acid (aspirin) in the diet of broilers maintained under heat stress conditions.
Topics: Animals; Ascorbic Acid; Aspirin; Body Weight; Chickens; Diet; Hot Temperature; Male; Stress, Physiol | 1988 |
Antiinflammatory activities of copper-aspirinate and aspirin in adjuvant arthritic rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experi | 1988 |
Effect of aspirin on experimental diabetic nephropathy.
Topics: Animals; Aspirin; Basement Membrane; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Di | 1987 |
Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide initiation and sodium saccharin promotion of urinary bladder carcinogenesis in male F344 rats.
Topics: Animals; Aspirin; Body Weight; Cocarcinogenesis; FANFT; Hydrogen-Ion Concentration; Male; Rats; Rats | 1986 |
Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Body Weight; Female; Humans; Infusions, Par | 1986 |
Strain-related susceptibility to nephrotoxicity induced by aspirin and phenylbutazone in rats.
Topics: Animals; Aspirin; Body Weight; Diuresis; Female; Kidney Papillary Necrosis; Male; Organ Size; Phenyl | 1986 |
Prostaglandins and aminoglycoside nephrotoxicity.
Topics: Analysis of Variance; Animals; Aspirin; Blood Urea Nitrogen; Body Weight; Creatinine; Drug Interacti | 1985 |
The effect of calcium acetylsalicylate on the content and distribution of mucus in the rat stomach.
Topics: Aminosalicylic Acids; Animals; Aspirin; Body Weight; Calcium; Gastric Mucosa; Male; Mucus; Rats; Sta | 1970 |
Gastric mucosal damage induced by non-steroid anti-inflammatory agents in rats of different ages.
Topics: Age Factors; Animals; Anti-Inflammatory Agents; Aspirin; Body Weight; Dose-Response Relationship, Dr | 1972 |
Correlations between pathological changes in the hind paws of rats with adjuvant arthritis and their response to anti-inflammatory and analgesic drugs.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Body Temperature; Bod | 1973 |
The prophylactic and therapeutic effects of gold sodium thiomalate against adjuvant-induced polyarthritis in rats.
Topics: Adjuvants, Immunologic; Animals; Arthritis; Aspirin; Blood Sedimentation; Body Weight; Disease Model | 1973 |
Ultrastructural alterations of hepatic microbodies.
Topics: Anilides; Animals; Aspirin; Benzoates; Body Weight; Carcinoma, Hepatocellular; Kidney; Liver; Liver | 1966 |
Infantile diarrhoea in a population of low socio-economic group.
Topics: Ascaris; Aspirin; Body Weight; Diarrhea, Infantile; Diet; Entamoeba histolytica; Escherichia coli; F | 1971 |
Effects of phentolamine mesylate and propranolol hydrochloride on aspirin-induced gastric lesions and gastric secretions in the rat.
Topics: Animals; Aspirin; Body Weight; Gastric Mucosa; Male; Phentolamine; Propranolol; Pylorus; Rats; Stoma | 1974 |
[Embryotoxic and teratogenic effects of acetylsalicylic acid and an acetylsalicylic acid containing combination].
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Aspirin; Body Weight; Brain; Dose-Response | 1974 |
Effects of salicylates on the canine stomach: a morphological and histochemical study.
Topics: Administration, Oral; Animals; Aspirin; Autopsy; Autoradiography; Biopsy; Body Weight; Dogs; Epithel | 1972 |
Aspirin-induced gastrointestinal microbleeding in dogs.
Topics: Analysis of Variance; Animals; Aspirin; Body Weight; Dogs; Dose-Response Relationship, Drug; Feces; | 1973 |
Antagonism of cholera enterotoxin by anti-inflammatory agents in the rat.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Aspirin; Body Fluids; Body Weight; Cholera; | 1972 |
Papillary necrosis in the Gunn rat: rapid induction by analgesics.
Topics: Analgesics; Animals; Aspirin; Bilirubin; Body Weight; Caffeine; Drug Combinations; Female; Hyperbili | 1972 |
The influence of pregnancy on the acute toxicity of various compounds in mice.
Topics: Animals; Aspirin; Body Weight; Chlorpromazine; Colchicine; Female; Fetus; Folic Acid; Iron-Dextran C | 1972 |
Inhibition of unilateral ovarian compensatory hypertrophy in the rat by ingestion of aspirin.
Topics: Animals; Aspirin; Body Weight; Castration; Diet; Female; Gonadotropins, Pituitary; Hypertrophy; Orga | 1973 |
Delayed manifestation of ultraviolet reaction in the guinea-pig caused by anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Body Weight; Erythema; Guinea Pigs; Indomethacin; Permea | 1973 |
Effects of chronic acetylsalicylate administration on several nutritional and biochemical parameters in rats fed diets of varied thiamin content.
Topics: Animals; Aspirin; Body Weight; Diet Therapy; Male; Mitochondria, Liver; Nutritional Physiological Ph | 1973 |
Interactions of aspirin, indomethacin and other drugs in adjuvant-induced arthritis in the rat.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Body Weight; Chlorpromazine; C | 1973 |
Further observations on mesenteric vasoconstriction, survival and the clotting defect after endotoxin administration.
Topics: Aminophylline; Animals; Aspirin; Blood Coagulation Disorders; Body Weight; Cats; Dextrans; Endotoxin | 1973 |
Effects of various drugs on longevity in female C57BL-6J mice.
Topics: Acetaminophen; Age Factors; Analgesics; Animals; Aspirin; Body Weight; Buffers; Cell Membrane; Chemi | 1973 |
Structure of hepatic microbodies in rats treated with acetylsalicylic acid, clofibrate, and dimethrin.
Topics: Animals; Aspirin; Benzyl Compounds; Body Weight; Carboxylic Acids; Cholesterol; Chrysanthemum cinera | 1974 |
Antiarthritic and antiinflammatory effects of certain prostaglandins.
Topics: Adrenal Glands; Animals; Anti-Inflammatory Agents; Arthritis; Aspirin; Blood Sedimentation; Body Wei | 1972 |
Effect of histidine, histamine, and aspirin on sulfur-35 metabolism in zinc-deficient chick bone.
Topics: Animal Nutritional Physiological Phenomena; Animals; Aspirin; Body Weight; Bone and Bones; Bone Dise | 1972 |
Adjuvant-induced arthritis in rats. II. Drug effects on physiologic, biochemical and immunologic parameters.
Topics: Animals; Anti-Inflammatory Agents; Antibodies; Arthritis; Aspirin; Body Weight; Cyclophosphamide; Di | 1971 |
Effects of topical hydrocortisone and acetylsalicylic acid on the primary lesion of adjuvant-induced arthritis.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents; Arthritis; Aspirin | 1971 |
The acute rectal toxicity of acetylsalicylic acid.
Topics: Adrenal Glands; Animals; Aspirin; Ataxia; Body Weight; Brain; Coma; Diarrhea; Diuresis; Dyspnea; Fee | 1966 |
Pharmacological studies of a new anti-inflammatory drug, 1-phenylsulfonyl-5,5-diphenylhydantoin (PC-796) in experimental animals. II. Toxicological and general pharmacological properties.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Autonomic Nervous System; Blood Circulation; Blood Gluco | 1970 |
Mode of action of aspirin. Effect of dietary aspirin on mitochondrial pyruvate metabolism in normal and thiamine-deficient rats.
Topics: Acetoacetates; Adenosine Triphosphate; Adipose Tissue; Animals; Aspirin; Bicarbonates; Blood Glucose | 1971 |
Polyarthritis in obese patients with intestinal bypass.
Topics: Adolescent; Adult; Arthritis; Aspirin; Body Height; Body Weight; Colon; Dehydration; Female; Humans; | 1971 |
[Enteric aspirin tablets and the salicylate concentration in the plasma in the morning].
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Body Weight; Circadian Rhythm; Female; Humans; Intestin | 1968 |
Studies of analgesic and anticonvulsant activity in mice by high-frequency electrical stimulation.
Topics: Age Factors; Analgesics; Animals; Anticonvulsants; Aspirin; Body Weight; Electric Stimulation; Elect | 1969 |
The effects of salicylates on growth in immature rats.
Topics: Animals; Animals, Newborn; Aspirin; Body Weight; Growth; Humans; Infant, Newborn; Rats; Salicylates; | 1966 |